Search results
Alzheimer’s drug from Eli Lilly that can slow brain-robbing disease backed by FDA advisers
Fortune· 49 minutes agoFood and Drug Administration advisers voted unanimously that the drug’s ability to slow the disease outweighs its risks, including side ...
Wolfe Research bullish on Akero stock, cites NASH treatment potential By Investing.com
Investing.com· 29 minutes agoThe firm believes that as investors become more confident about the potential market for NASH...
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
CNBC· 14 hours agoA panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly'...
Alzheimer’s drug from Eli Lilly wins backing of FDA committee
Washington Post· 13 hours agoMuch of the committee’s discussion focused on the safety of the drug, donanemab, which works by...
New Alzheimer’s treatment drug gets support from FDA advisory panel
WXYZ-TV Detroit· 13 hours agoIf approved by the FDA, it would become the second Alzheimer’s drug on the market. Alzheimer’s is an incurable disease that affects nearly ...
What's the difference between California's legislative public safety package and Prop 47 reform...
KCRA 3 Sacramento· 7 hours agoA major political fight over public safety in California is heating up as Democratic leaders attempt...
Lilly's Alzheimer's drug faces delayed reckoning
Axios· 22 hours agoThe outlook for the latest experimental drug shown to delay Alzheimer's disease will come into focus Monday, when Food and Drug Administration ...
Trending tickers: Apple, Lily, AMD and FirstGroup
Yahoo Finance UK· 35 minutes agoThe experts concluded, by an 11-0 vote, that the drug’s benefits outweigh its risks, despite some safety concerns. “I thought the evidence ...
Alzheimer’s drug that can slow disease gets backing from FDA advisers
FOX 5 San Diego· 14 hours agoWASHINGTON (AP) — A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal...
US medical advisers vote to recommend Eli Lilly Alzheimer drug
Medical Xpress· 2 hours agoThe Food and Drug Administration (FDA) in March pushed back a planned meeting of experts to evaluate the safety of the intravenously-injected antibody.